NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer

There is a need for biomarkers to improve the clinical benefit from systemic treatment of colorectal cancer. We designed a prospective, clinical study where patients receiving regorafenib as last-line treatment had sequential blood samples drawn. Effect and toxicity was monitored. The primary clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Lars Henrik, Olesen, René, Petersen, Lone Noergaard, Boysen, Anders Kindberg, Andersen, Rikke Fredslund, Lindebjerg, Jan, Nottelmann, Lise, Thomsen, Caroline Emilie Brenner, Havelund, Birgitte Mayland, Jakobsen, Anders, Hansen, Torben Frøstrup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896074/
https://www.ncbi.nlm.nih.gov/pubmed/31731482
http://dx.doi.org/10.3390/cancers11111649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896074/
https://www.ncbi.nlm.nih.gov/pubmed/31731482
http://dx.doi.org/10.3390/cancers11111649

Ejemplares similares